Literature DB >> 36264881

A global, regional, and national survey on burden and Quality of Care Index (QCI) of bladder cancer: The global burden of disease study 1990-2019.

Amirali Karimi1, Parnian Shobeiri1, Sina Azadnajafabad1, Masoud Masinaei1,2, Negar Rezaei1,3, Ali Ghanbari1, Nazila Rezaei1, Mahtab Rouhifard1, Sarvenaz Shahin1, Mohammad-Mahdi Rashidi1, Mohammad Keykhaei1,4, Ameneh Kazemi1, Erfan Amini5, Bagher Larijani3, Farshad Farzadfar1,3.   

Abstract

INTRODUCTION: Bladder cancer (BCa) is the second most common genitourinary cancer and among the leading causes of cancer-related deaths. We aimed to assess BCa quality of care (QOC) utilizing a novel multi-variable quality of care index (QCI).
MATERIALS AND METHODS: Data were retrieved from the Global Burden of Disease 1990-2019 database. QCI scores were calculated using four indices of prevalence-to-incidence ratio, Disability-Adjusted Life Years-to-prevalence ratio, mortality-to-incidence ratio, and Years of Life Lost-to-Years Lived with Disability ratio. We used principal component analysis to allocate 0-100 QCI scores based on region, age groups, year, and gender.
RESULTS: Global burden of BCa is on the rise with 524,305 (95% UI 475,952-569,434) new BCa cases and 228,735 (95% UI 210743-243193) deaths in 2019, but age-standardized incidence and mortality rates did not increase. Global age-standardized QCI improved from 75.7% in 1990 to 80.9% in 2019. The European and African regions had the highest and lowest age-standardized QCI of 89.7% and 37.6%, respectively. Higher Socio-demographic index (SDI) quintiles had better QCI scores, ranging from 90.1% in high SDI to 30.2% in low SDI countries in 2019; however, 5-year QCI improvements from 2014 to 2019 were 0.0 for high and 4.7 for low SDI countries.
CONCLUSION: The global QCI increased in the last 30 years, but the gender disparities remained relatively unchanged despite substantial improvements in several regions. Higher SDI quintiles had superior QOC and less gender- and age-based inequalities compared to lower SDI countries. We encourage countries to implement the learned lessons and improve their QOC shortcomings.

Entities:  

Mesh:

Year:  2022        PMID: 36264881      PMCID: PMC9584505          DOI: 10.1371/journal.pone.0275574

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.752


  47 in total

1.  Screening for bladder cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2011-08-16       Impact factor: 25.391

2.  Long-term impact of arsenic in drinking water on bladder cancer health care and mortality rates 20 years after end of exposure.

Authors:  Mario I Fernández; J Francisco López; Bruno Vivaldi; Fernando Coz
Journal:  J Urol       Date:  2012-01-15       Impact factor: 7.450

3.  Trends in socio-economic inequalities in bladder cancer incidence in Canada: 1992-2010.

Authors:  Ryan Densmore; Mohammad Hajizadeh; Min Hu
Journal:  Can J Public Health       Date:  2019-06-17

Review 4.  Epidemiology and risk factors of urothelial bladder cancer.

Authors:  Maximilian Burger; James W F Catto; Guido Dalbagni; H Barton Grossman; Harry Herr; Pierre Karakiewicz; Wassim Kassouf; Lambertus A Kiemeney; Carlo La Vecchia; Shahrokh Shariat; Yair Lotan
Journal:  Eur Urol       Date:  2012-07-25       Impact factor: 20.096

5.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

6.  Global, regional, and national burden and quality of care index of endocarditis: the global burden of disease study 1990-2019.

Authors:  Sara Momtazmanesh; Sahar Saeedi Moghaddam; Elaheh Malakan Rad; Sina Azadnajafabad; Narges Ebrahimi; Esmaeil Mohammadi; Mahtab Rouhifard; Negar Rezaei; Masoud Masinaei; Nazila Rezaei; Mohammad Keykhaei; Arya Aminorroaya; Azin Ghamari; Bagher Larijani; Farshad Farzadfar
Journal:  Eur J Prev Cardiol       Date:  2022-05-27       Impact factor: 7.804

Review 7.  Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD-SIU joint consultation on bladder cancer.

Authors:  Mario I Fernández; Maurizio Brausi; Peter E Clark; Michael S Cookson; H Barton Grossman; Makarand Khochikar; Lambertus A Kiemeney; Bernard Malavaud; Rafael Sanchez-Salas; Mark S Soloway; Robert S Svatek; Raghunandan Vikram; Alina Vrieling; Ashish M Kamat
Journal:  World J Urol       Date:  2018-08-13       Impact factor: 4.226

Review 8.  Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement.

Authors:  Gretchen A Stevens; Leontine Alkema; Robert E Black; J Ties Boerma; Gary S Collins; Majid Ezzati; John T Grove; Daniel R Hogan; Margaret C Hogan; Richard Horton; Joy E Lawn; Ana Marušić; Colin D Mathers; Christopher J L Murray; Igor Rudan; Joshua A Salomon; Paul J Simpson; Theo Vos; Vivian Welch
Journal:  Lancet       Date:  2016-06-28       Impact factor: 79.321

9.  Gender inequalities in the promptness of diagnosis of bladder and renal cancer after symptomatic presentation: evidence from secondary analysis of an English primary care audit survey.

Authors:  Georgios Lyratzopoulos; Gary A Abel; Sean McPhail; Richard D Neal; Gregory P Rubin
Journal:  BMJ Open       Date:  2013-06-24       Impact factor: 2.692

10.  Global, regional, and national burden and quality of care index (QCI) of thyroid cancer: A systematic analysis of the Global Burden of Disease Study 1990-2017.

Authors:  Sina Azadnajafabad; Sahar Saeedi Moghaddam; Esmaeil Mohammadi; Negar Rezaei; Erfan Ghasemi; Nima Fattahi; Arya Aminorroaya; Reza Azadnajafabad; Armin Aryannejad; Nazila Rezaei; Shohreh Naderimagham; Vahid Haghpanah; Ali H Mokdad; Hossein Gharib; Farshad Farzadfar; Bagher Larijani
Journal:  Cancer Med       Date:  2021-03-05       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.